Under the collaboration, researchers are enabled to use NanoCellect’s platform for cell sorting, followed by scRNA-seq on Fluent’s novel, instrument-free platform based on pre-templated instant partitions (PIPseq)
Fluent BioSciences partners with NanoCellect. (Credit: Louis Reed on Unsplash)
Fluent BioSciences has teamed up with NanoCellect Biomedical to improve the resolution and effectiveness of single-cell RNA sequencing (scRNA-seq) analysis of rare cell populations.
Under the collaboration, researchers are enabled to use NanoCellect’s platform for cell sorting, followed by scRNA-seq on Fluent’s novel, instrument-free platform based on pre-templated instant partitions (PIPseq).
The combined solution is expected to be highly effective for a wide range of single-cell applications across oncology, immunology and neuroscience.
Its PIPseq technology enables highly sensitive and unbiased preparation of proteins and nucleic acids for a wide range of applications, said the company.
Fluent BioSciences co-founder and CEO Sepehr Kiani said: “For single-cell sequencing to truly become mainstream researchers need benchtop solutions that fit their diverse experimental needs rather than compromising the science with complex, expensive, and inflexible platforms.
“I am very pleased that Fluent and NanoCellect are able to leverage and combine the unique advantages of our respective technologies to expand the use of single-cell RNA sequencing for rare cell populations.”
Fluent is a biotechnology company focused on advancing the understanding of single-cell biology through accessible, affordable, and scalable solutions.
The scRNA-seq is said to enable the identification of rare cell types with unique gene expression profiles, detailed annotation of cell types in the human body and develop new biomarkers.
NanoCellect is engaged in the development and production of advanced microfluidic-based cell sorting solutions that are affordable, compact, and easy to use.
Its portfolio will help biomedical scientists analyse and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research, said the company.
NanoCellect president and co-founder Jose Morachis said: “Reliable and reproducible sample preparation is critically important to the scRNAseq workflow.
“NanoCellect’s WOLF and WOLF G2 Cell Sorters can function as a valuable step in the scRNA-seq workflow by isolating only cells of interest while removing dead cells and debris, thus improving scRNA-seq resolution of rare cell populations of interest and overall sequencing data quality.”
Earlier this year, Fluent secured a $1.7m Small Business Innovation Research (SBIR) Phase II grant from the National Institute of General Medical Sciences.
The company dedicated the funding to support its scRNA-Seq products and services.